Chorionic villus sampling

Chorionic villus sampling. It is a form of prenatal diagnosis performed during early pregnancy to detect genetic abnormalities in a developing fetus. The procedure involves obtaining a small sample of chorionic villi, which are finger-like projections on the chorion that share the fetus's genetic makeup. First performed in the late 1960s, it became a widely adopted clinical tool following refinement by researchers like Giuseppe Simoni in the 1980s. This diagnostic technique is typically offered following counseling at a genetic counseling clinic, often within a larger medical genetics department.

Procedure

The test is usually performed between the 10th and 13th weeks of gestation, as determined by an earlier ultrasonography exam. Under continuous ultrasound guidance, a physician accesses the placenta using either a transabdominal approach with a needle or a transcervical approach with a catheter. The chosen method often depends on the placenta's location relative to the cervix and the uterine position. The sample, consisting of chorionic villi, is then aspirated and sent to a cytogenetics laboratory for analysis. Key professional guidelines, such as those from the American College of Obstetricians and Gynecologists, standardize the technique to maximize safety. The entire process is typically completed as an outpatient procedure at a specialized prenatal diagnosis center.

Indications and uses

Primary indications include advanced maternal age, a previous pregnancy affected by a chromosomal abnormality, or an abnormal result from a first-trimester screening test like the nuchal translucency scan. It is a definitive diagnostic test for conditions such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). The sample can also be used for DNA-based testing to diagnose single-gene disorders like cystic fibrosis, sickle cell disease, or Tay-Sachs disease. Furthermore, it can determine fetal sex and diagnose certain X-linked disorders, which may inform management decisions. The test is often recommended after counseling by specialists at institutions like the National Society of Genetic Counselors.

Risks and complications

The most significant risk is pregnancy loss (miscarriage), with the procedure-related rate generally quoted as approximately 0.5-1% above the background risk. Other potential complications include vaginal spotting or bleeding, amniotic fluid leakage, or uterine infection (chorioamnionitis). Rarely, there is a risk of limb reduction defects when the procedure is performed very early, before 10 weeks. Maternal complications, such as Rh sensitization, can be mitigated with an injection of Rh immune globulin for Rh negative women. Continuous monitoring by organizations like the Centers for Disease Control and Prevention helps refine safety profiles.

Comparison with amniocentesis

The primary advantage over amniocentesis is its earlier timing; it can be performed several weeks before amniocentesis, which is typically done after 15 weeks. While both procedures diagnose chromosomal abnormalities, amniocentesis is the only one that can reliably detect open neural tube defects like spina bifida. The risk of pregnancy loss is comparable between the two when performed by experienced operators at centers like the Mayo Clinic. Amniocentesis analyzes fetal cells shed into the amniotic fluid, whereas this technique studies placental tissue, which can rarely lead to confined placental mosaicism.

Accuracy and reliability

The diagnostic accuracy for detecting major chromosomal abnormalities is very high, generally over 99%. The karyotype analysis from the villi provides a comprehensive view of the fetal chromosomes. However, the phenomenon of confined placental mosaicism, where the placenta has a different genetic constitution than the fetus, occurs in about 1-2% of cases and can occasionally lead to diagnostic uncertainty or false-positive results. In such instances, a follow-up amniocentesis may be recommended for confirmation. Laboratories accredited by the College of American Pathologists ensure stringent quality control for the cytogenetic analysis.

Ethical considerations

The procedure raises significant ethical issues common to prenatal diagnosis, primarily surrounding the potential for selective abortion based on test results. This intersects with debates on disability rights and the principles of reproductive autonomy. The ability to diagnose conditions like Down syndrome early in pregnancy can lead to complex decision-making for prospective parents. Furthermore, the use of the test for non-medical sex selection is widely condemned by professional bodies, including the American Congress of Obstetricians and Gynecologists. These considerations are often explored during pre-test genetic counseling sessions to ensure informed consent.